Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers

British Journal of Clinical Pharmacology

Volumn 58, Issue 1, 2004, Pages 20-25

  Sobue, Satoshi ^a   Tan, Keith ^b   Layton, Gary ^b   Eve, Malcolm ^c   Sanderson, J Brian ^d  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Bioavailability; Fluconazole; Fosfluconazole; Loading dose; Pharmacokinetics

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; FOSFLUCONAZOLE; PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BOLUS INJECTION; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EXCRETION; DRUG SAFETY; DRUG URINE LEVEL; HEADACHE; HEMOCONCENTRATION; HUMAN; INTERMETHOD COMPARISON; MALE; NAUSEA; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TREATMENT OUTCOME; URINARY EXCRETION;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FLUCONAZOLE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PHOSPHORIC ACID ESTERS;

EID: 3142619424     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02107.x     Document Type: Article

References (15)

1. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 662-78.
2. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658-90.
3. Troke PF. Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group. Eur J Clin Microbiol Infect Dis 1997; 16: 287-95.
4. Bentley A, Butters M, Green SP, et al. The discovery and process development of a commercial route to the water soluble prodrug, fosfluconazole. Org Process Res Dev 2002; 6: 109-12.
5. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42: 1105-9.
6. Andes D, van Ogtrop ML. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine model of disseminated candidiasis model. Antimicrob Agents Chemother 1999; 43: 2116-20.
7. Rex JH, Pfaller MA, Galgiani JN, et al. for the NCCLS Subcommittee on Antifungal Susceptibility Testing. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro and in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235-47.
8. Lee SC, Fung CP, Huang JS, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000; 44: 2715-8.
9. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12(Suppl 3): S318-S326.
10. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 24: 10-27.
11. SAS Institute Inc. SAS/SAT Users Guide, Version 6.09 4th edn. Cary. NC, SAS Institute Inc, 1994.
12. Marco F, Danes C, Almela M, et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis 2003; 46: 259-64.
13. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-9.
14. Safdar A, Chaturvedi V, Koll BS, Larone DH, Perlin DS, Armstrong D. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998-1999). Antimicrob Agents Chemother 2002; 46: 3268-72.
15. Datta K, Jain N, Sethi S, Rattan A, Casadevall A, Banerjee U. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care. J Antimicrob Chemother 2003; 52: 679-82.